Pancreatic cancer is a formidable health problem, representing the 10th most common malignancy in the United States and the 4th most common cause of all cancer deaths. The overall 5-year survival rate is 4%, making this disease a model tumor in which to address the specialized care issues of palliative medicine.
Methods
General considerations in both medical decision-making and symptom management are reviewed. Treatment of patients with locally unresectable, recurrent, or metastatic disease is individualized, based on considerations that include patient age, patient wishes, family influence, insurance constraints, and geographic practice variations.
Results
Success in managing progressive symptoms is needed to palliate patients with advanced pancreatic cancer. Common problems include biliary obstruction, depression, pain, intestinal obstruction, and fatigue.
Conclusions
Relief of pain and suffering associated with critical illness is required in managing patients with cancer. Pancreatic cancer is a model illness that mandates this need.
References
1.
JemalA., MurrayT., SamuelsA.Cancer statistics, 2003. CA Cancer J Clin.2003; 53: 5–26.
2.
ComptonC.C., MulvihillS.J.Prognostic factors in pancreatic carcinoma. Surg Oncol Clin N Am.1997; 6: 533–554.
3.
BramhallS.R., AllumW.H., JonesA.G.Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiology study. Br J Surg.1995; 82: 111–115.
4.
YeoC.J., CameronJ.L., LillemoeK.D.Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg.1995; 221: 721–733.
5.
WinnR.J.Obstacles to the accrual of patients to clinical trials in the community setting. Semin Oncol.1994(4 suppl 7); 21: 112–117.
6.
SlevinsM.L.Making decisions about palliative chemotherapy. In: ASCO Educational Book.1992.
7.
BravermanA.S.Medical oncology in the 1990s. Lancet.1991; 337: 901–902.
8.
KlasterskyJ.Supportive care: what for?Curr Opin Oncol.1995; 7: 303.
9.
MarkmanM.Introduction: treatment of malignancies poorly responsive to currently available antineoplastic therapy. Semin Oncol.1994; 21(4 suppl 7): 1–2.
10.
BailesJ.S.Cost aspects of palliative cancer care. Semin Oncol.1995; 22(2 suppl 3): 64–66.
11.
ChernyN., CoyleN., FoleyK.M.Guidelines in the care of the dying cancer patient. Hematol Oncol Clin North Am.1996; 10: 261–286.
12.
McCraryS.V., SwansonJ.W., YoungnerS.J.Physicians’ quantitative assessments of medical futility. J Clin Ethics.1994; 5: 100–105.
13.
SoxH.C.Jr, BlattM.A., HigginsM.C., eds. Medical Decision-Making.Boston, Mass: Butterworth-Heinemann; 1988.
14.
DaughertyC.K.The “cure” for cancer: can the media report the hope without the hype?J Clin Oncol.2002; 20: 3761–3764.
15.
MeyersF.J., LinderJ.Simultaneous care: disease treatment and palliative care throughout illness. J Clin Oncol.2003; 21: 1412–1415.
16.
PearlmanR.A.Inaccurate predictions of life expectancy. Dilemmas and opportunities. Arch Intern Med.1988; 148: 2537–2538.
17.
Addington-HallJ.M., MacDonaldL.D., AndersonH.R.Can the Spitzer Quality of Life Index help to reduce prognostic uncertainty in terminal care?Br J Cancer.1990; 62: 695–699.
18.
SchonwetterR.S., TeasdaleT.A., StoreyP.Estimation of survival time in terminal cancer patients: an impedance to hospice admissions?Hosp J.1990; 6: 65–79.
19.
DelVecchio GoodM.J., GoodB.J., SchafferC.American oncology and the discourse on hope. Cult Med Psychiatry.1990; 14: 59–79.
20.
KodishE., PostS.G.Oncology and hope. J Clin Oncol.1995; 13: 1817.
21.
LamontE.B., ChristakisN.A.Some elements of prognosis in terminal cancer. Oncology (Huntington).1999; 13: 1165–1180.
22.
ChristakisN.A.Death Foretold: Prophecy and Prognosis in Medical Care.Chicago, Ill: University of Chicago Press; 1999.
23.
EmanuelE.J., EmanuelL.L.The promise of a good death. Lancet.1998; 351(suppl 2): SII21–SII29.
24.
FieldM.J., CasselC.K., eds. Approaching Death: Improving Care at the End of Life. Committee on Care at the End of Life, Division of Health Care Services, Institute of Medicine. Washington, DC: National Academy Press; 1997.
25.
A controlled trial to improve care for seriously ill hospitalized patients.The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators. JAMA.1995; 274: 1591–1598.
26.
GrossmanS.A., SheidlerV.R., SwedeenK.Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manage.1991; 6: 53–57.
27.
el-KamarF.G., GrossbardM.L., KozuchP.S.Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care. Oncologist.2003; 8: 18–34.
28.
TarnaskyP.R., CottonP.B.Randomized trial of prevention of biliary stent occlusion by ursodeoxycholic acid plus norfloxacin. Gastrointest Endosc.1995; 42: 103–104.
29.
LammerJ., HauseggerK.A., FluckigerF.Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents. Radiology.1996; 201: 167–172.
30.
FrasI., LitinE.M., PearsonJ.S.Comparison of psychiatric symptoms in carcinoma of the pancreas with those in some other intraabdominal neoplasms. Am J Psychiatry.1967; 123: 1553–1562.
31.
JoffeR.T., RubinowD.R., DenicoffK.D.Depression and carcinoma of the pancreas. Gen Hosp Psychiatry.1986; 8: 241–245.
32.
MassieM.J., HollandJ.C.The cancer patient with pain: psychiatric complications and their management. Med Clin North Am.1987; 71: 243–258.
33.
FoleyK.M.Pain assessment and cancer pain syndromes. In: DoyleD., HanksG.W.C., MacDonaldN., eds. Oxford Textbook of Palliative Medicine.2nd ed.Oxford, New York: Oxford University Press; 1998.
34.
KelsenD.P., PortenoyR.K., ThalerH.T.Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol.1995; 13: 748–755.
35.
AngelinoA.F., TreismanG.J.Major depression and demoralization in cancer patients: diagnostic and treatment considerations. Support Care Cancer.2001; 9: 344–349.
BresciaF.J., PortenoyR.K., RyanM.Pain, opioid use, and survival in hospitalized patients with advanced cancer. J Clin Oncol.1992; 10: 149–155.
38.
SolomonM.Z., O'DonnellL., JenningsB.Decisions near the end of life: professional views on life-sustaining treatments. Am J Public Health.1993; 83: 14–23.
39.
LevinD.N., CleelandC.S., DarR.Public attitudes toward cancer pain. Cancer.1985; 56: 2337–2339.
40.
SaundersC.Appropriate treatment, appropriate death. In: SaundersD.C., ed. The Management of Terminal Malignant Disease.London, Baltimore, Md: Edward Arnold; 1984.
41.
KawamataM., IshitaniK., IshikawaK.Comparison between celiac plexus block and morphine treatment on quality of life in patients with pancreatic cancer pain. Pain.1996; 64: 597–602.
42.
SeamansD.P., WongG.Y., WilsonJ.L.Interventional pain therapy for intractable abdominal cancer pain. J Clin Oncol.2000; 18: 1598–1600.
43.
SmithT.J., StaatsP.S., DeerT.Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol.2002; 20: 4040–4049.
PhilipJ., LickissN., GrantP.T.Corticosteroids in the management of bowel obstruction on a gynecological oncology unit. Gynecol Oncol.1999; 74: 68–73.
46.
MangiliG., FranchiM., MarianiA. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol.1996; 61: 345–348.
47.
BaronT.H.Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. N Engl J Med.2001; 344: 1681–1687.
48.
MiaskowskiC., PortenoyR.K.Update on the assessment and management of cancer-related fatigue. Principles and Practice of Supportive Oncology Updates.1998; 1: 1–10.
49.
SimonA.M., ZittounR.Fatigue in cancer patients. Curr Opin Oncol.1999; 11: 244–249.
